Synergistic Antibacterial Effects of Chitosan-Caffeic Acid Conjugate against Antibiotic-Resistant Acne-Related Bacteria

Ji-Hoon Kim 1, Daegung Yu 2, Sung-Hwan Eom 3, Song-Hee Kim 1, Junghwan Oh 4,5, Won-Kyo Jung 4,5 and Young-Mog Kim 1,5,*

1 Department of Food Science and Technology, Pukyong National University, Busan 48547, Korea; kjhy1126@naver.com (J.-H.K.); ksonghee93@gmail.com (S.-H.K.)
2 Department of Chemical and Biological Engineering, University of Saskatchewan, Saskatoon, SK S7N 5C5, Canada; day852@mail.usask.ca
3 Korea Food Research Institute, Sungnam 13539, Korea; dalgoo52@gmail.com
4 Department of Biomedical Engineering, Pukyong National University, Busan 48513, Korea; jungoh@pknu.ac.kr (J.O.); wkjung@pknu.ac.kr (W.-K.J.)
5 Marine-Integrated Bionics Research Center, Pukyong National University, Busan 48513, Korea
* Correspondence: ymkim@pknu.ac.kr; Tel.: +82-051-629-5832

Received: 17 February 2017; Accepted: 6 June 2017; Published: 8 June 2017

Abstract: The object of this study was to discover an alternative therapeutic agent with fewer side effects against acne vulgaris, one of the most common skin diseases. Acne vulgaris is often associated with acne-related bacteria such as Propionibacterium acnes, Staphylococcus epidermidis, Staphylococcus aureus, and Pseudomonas aeruginosa. Some of these bacteria exhibit a resistance against commercial antibiotics that have been used in the treatment of acne vulgaris (tetracycline, erythromycin, and lincomycin). In the current study, we tested in vitro antibacterial effect of chitosan-phytochemical conjugates on acne-related bacteria. Three chitosan-phytochemical conjugates used in this study exhibited stronger antibacterial activity than that of chitosan (unmodified control). Chitosan-caffeic acid conjugate (CCA) showed the highest antibacterial effect on acne-related bacteria along with minimum inhibitory concentration (MIC; 8 to 256 µg/mL). Additionally, the MIC values of antibiotics against antibiotic-resistant P. acnes and P. aeruginosa strains were dramatically reduced in combination with CCA, suggesting that CCA would restore the antibacterial activity of the antibiotics. The analysis of fractional inhibitory concentration (FIC) indices clearly revealed a synergistic antibacterial effect of CCA with antibiotics. Thus, the median sum of FIC (∑FIC) values against the antibiotic-resistant bacterial strains ranged from 0.375 to 0.533 in the combination mode of CCA and antibiotics. The results of the present study suggested a potential possibility of chitosan-phytochemical conjugates in the control of infections related to acne vulgaris.

Keywords: acne vulgaris; antibiotic resistance; chitosan-phytochemical conjugates; synergistic antibacterial effect

1. Introduction

Acne vulgaris is one of the most commonly observed skin diseases, affecting young adults (11–30 years). It can cause permanent physical scarring resulting in intense emotional scars, which might lead to clinical depression and social phobias [1,2]. Propionibacterium acnes, Staphylococcus epidermidis, and S. aureus are known skin pathogenic bacteria associated with acne vulgaris. These bacteria are related to the development of inflammation and abnormal follicular keratinization [3]. P. acnes develops inflammatory acne by chemotactically-attracted neutrophils by metabolizing sebaceous triglycerides into fatty acids [4,5]. Normally, antibiotics are used as acne treatment to kill the bacteria. Among them,
erythromycin, lincomycin, and tetracycline are usually chosen for the antibiotic therapy [6,7]. However, long-term usage of antibiotics is associated with complications, such as outbreaks of resistant bacteria, immune hypersensitivity, and organ damage [5,8]. Therefore, developing alternative therapeutic agents with fewer side effects and strong antibacterial effect need to be researched.

To overcome the problem of side effects, several candidate substrates, such as traditional Chinese medicines, essential oils, herbs, and chitosan, have been investigated for the treatment of acne [9,10]. Among several candidate substrates, chitosan is an especially attractive resource to develop marine-derived antimicrobial agents due to their low cost and suitability for mass production [11,12]. Chitosan is one of mucopolysaccharides of marine origin, being biodegradable, biocompatible and having low toxicity. Chitosan has been used in the pharmaceutical industry due to its anti-inflammatory, antioxidant, and enzyme-inhibitory properties [13–15]. Furthermore, chitosan offers the advantage of easy chemical modifications on account of the primary amino group at the 2-position of each polymer subunit with other biological activities [16]. Therefore, the development of novel chitosan derivatives with functional properties is increasingly in demand [17]. However, as described above, most studies related to chitosan and its derivatives have been focused on the biological activities, such as antioxidant, antitumor, and anti-inflammatory effects, not antimicrobial activity [18–21]. Our group previously developed chitosan derivatives conjugated with phytochemicals (caffeic acid, ferulic acid, and sinapic acid), which exhibited strong antibacterial activity against pathogenic bacteria [14,21]. Thus, as part of our ongoing investigation on chitosan-conjugated derivatives for the treatment of acne vulgaris, the present investigation reports the antimicrobial activity of chitosan derivatives conjugated against P. acnes. The results of this study will provide valuable information on the development of an alternative acne vulgaris therapeutic agent.

2. Results

2.1. Antibacterial Effect of Chitosan-Phytochemical Conjugates against Acne-Related Bacteria

Hydroxycinnamic acids (HAs) (having sinapic acid, caffeic acid, and ferulic acid) are naturally occurring phytochemicals from plants and have been used in pharmaceuticals, cosmetics, and the food industry [21–23]. In this study, chitosan-phytochemical conjugates were synthesized by conjugating HAs with chitosan following the previous method [17,24]. It was then assessed for the antibacterial activity of chitosan-phytochemical conjugates against acne-related bacteria. According to Lee et al. [25], Chitosonic® acid can be used as a potent antimicrobial agent against Gram-positive bacteria, Gram-negative bacteria, and fungi. However, they did not employ the most common antibacterial method such as the tube dilution method and agar dilution methods. In order to determine its antibacterial effect of chitosan-phytochemical conjugates quantitatively, the antibacterial activity of the chitosan-phytochemical conjugates against acne-related bacteria was investigated using an MIC assay. The MIC values of the chitosan-phytochemical conjugates were evaluated by the two-fold serial dilution method, and the results are given in Table 1. The MIC of the unconjugated chitosan was in the range of 16–512 µg/mL against acne-related bacteria. Moreover, the chitosan-phytochemical conjugates had lower MIC values than these of the unconjugated chitosan ranging from 8 to 256 µg/mL. The highest antibacterial activity was observed in the treatment of CCA. The MICs of CCA were determined in a range of 8–256 µg/mL against acne-related bacteria tested in this study. CFA and CSA showed MIC values of 16–256 µg/mL against acne-related bacteria.
Table 1. Minimum inhibitory concentrations (MIC) of the chitosan-phytochemical conjugates against acne-related bacteria.

| Strain                  | MIC (µg/mL)          |
|-------------------------|----------------------|
|                         | CCA ¹ | CFA ² | CSA ³ | Unmodified Chitosan |
| Staphylococcus aureus KCTC 1927 | 8     | 16    | 16    | 16                  |
| Staphylococcus epidermidis KCTC 1370 | 64    | 64    | 64    | 64                  |
| Pseudomonas aeruginosa KCTC 1637 | 16    | 32    | 32    | 32                  |
| Propionibacterium acnes KCTC 3314 | 256   | 256   | 256   | 512                 |
| P. acnes isolate 2874 | 256   | 256   | 256   | 512                 |
| P. acnes isolate 2875 | 128   | 256   | 256   | 256                 |

¹ CCA, chitosan-caffeic acid; ² CFA, chitosan-ferulic acid; ³ CSA, chitosan-sinapic acid.

The antimicrobial activities of essential oils, medicinal plants, and chemicals against *P. acnes* have been reported. Zu et al. [10] previously reported that the MICs of the essential oils from thyme, cinnamon, and rose against *P. acnes* were 0.0016% (v/v), 0.0016% (v/v), and 0.031% (v/v). The duzhong extract showed the greatest antimicrobial activity against *P. acnes* with an MIC of 0.5 mg/mL and the yerba mate extract showed moderate antibacterial activity against *P. acnes* with an MIC of 1.0 mg/mL [26]. Although the antimicrobial activity of the chitosan-phytochemical conjugate against methicillin-resistant *S. aureus* (MRSA), foodborne pathogens, and fish pathogens are reported, a limited number of studies have been performed to assess the antimicrobial activity of chitosan-phytochemical conjugates against *P. acnes* [21,27,28].

2.2. Antibiotic Resistance of Acne-Related Bacteria against Commercial Antibiotics

The generally available therapeutic option for the treatment of acne vulgaris is an antibiotic application to kill the acne-related bacteria. Tetracycline, erythromycin, and lincomycin are the primary choice of antibiotics in the treatment of acne-related bacterial infections [6,7]. With the increase in antibiotic application, the increased prevalence of antibiotic-resistant bacteria has been reported [29]. Additionally, the antibiotic resistance of acne-related bacteria has been previously reported. According to the report by Lee et al. [30], *P. acnes* is highly resistant to erythromycin (an MIC of 2048 µg/mL). However, *S. epidermidis* and *S. aureus* were sensitive to erythromycin, tetracycline, and lincomycin in the MIC ranges of 0.125 µg/mL to 8 µg/mL. In addition, Oprica et al. [31] reported that *P. acnes* has a high resistance to erythromycin and clindamycin. The antibiotic resistance patterns of acne-related pathogens used in the present study were qualitatively determined by an MIC assay (Table 2). MIC breakpoints can assist in determining if an antibacterial is potentially useful in the treatment of a bacterial infection. To compare the antibiotic resistance of acne-related bacteria against commercial antibiotics, the antibiotic-resistant profile of each bacteria was then determined based on the analysis of the MIC breakpoint [32].

Table 2. Minimum inhibitory concentration (MIC) of tetracycline, erythromycin, and lincomycin against acne-related bacteria.

| Strain                  | MIC (µg/mL) |
|-------------------------|-------------|
|                         | Erythromycin | Lincomycin | Tetracycline |
| *Staphylococcus aureus KCTC 1927* | 2           | 4          | 0.5         |
| *Staphylococcus epidermidis KCTC 1370* | 0.125       | 0.25       | 2           |
| *Pseudomonas aeruginosa KCTC 1637* | 16          | 64         | 0.125       |
| *Propionibacterium acnes KCTC 3314* | 1024        | 1024       | 32          |
| *P. acnes isolate 2874* | 1024        | 1024       | 16          |
| *P. acnes isolate 2875* | 0.125       | 1          | 0.125       |
| Soussy’s MIC breakpoints ¹ | 1–4 ¹        | 2–8 ¹      | 4–8 ¹       |

¹ Soussy et al. [32].
2.3. Synergistic Antibacterial Effect between CCA and Antibiotics against Acne-Related Bacteria

With the emergence of multidrug-resistant bacteria, the need for new antibiotics or therapeutic agents has increased [33,34]. One of the effective strategies in developing alternative therapies is restoring antibiotic efficacy with non-antibiotic natural products against drug-resistant bacteria [14,35–37]. Based on these reports, an interaction between chitosan-phytochemicals and commercial antibiotics were estimated by the checkerboard method, as stated above, and the results are presented in Table 3. Among the chitosan-phytochemicals, CCA presented the highest antibacterial activity against acne-related bacteria and, hence, CCA was chosen for further studies.

As shown in Table 2, the MICs of tetracycline, erythromycin, and lincomycin against antibiotic-resistant \( P. acnes \) strains ranged from 16 to 1024 µg/mL. However, the MICs against the \( P. acnes \) strains were dramatically decreased in combination with CCA (Table 3). The MICs of tetracycline against \( P. acnes \) KCTC 3314 and isolate 2874 strains were fairly reduced, up to 4 µg/mL when applied in combination with 256 µg/mL of CCA. Comparing the MICs of tetracycline alone (16 to 32 µg/mL), the MICs decreased two- to three-fold in the combination of tetracycline-CCA. In addition, the MICs of erythromycin and lincomycin against \( P. acnes \) strains were also dramatically reduced two- to four-fold in combination with CCA. As a result, the median FIC indices were from 0.502 to 0.504. Thus, these results indicated that the combination of CCA with commercial antibiotics used in acne infection resulted in a synergistic effect against the antibiotic-resistant \( P. acnes \) strains. In analogy to the antibacterial effect against the antibiotic-resistant \( P. acnes \) strains, a synergistic antibacterial effect against an antibiotic-resistant \( P. aeruginosa \) KCTC 1637 strain was also observed in CCA-erythromycin and CCA-lincomycin combinations. The median \( \sum FIC \) indices were in the range of 0.375–0.500, indicating a marked synergy effect between lincomycin and CCA and a weak synergy between erythromycin and CCA. These results were also in agreement with the research of Eom et al. [14] that chitosan-derived conjugates clearly reversed the antibacterial activity of \( \beta \)-lactam antibiotics against MRSA in the combination mode. The median \( \sum FIC \) indices were in the ranges of 0.375–0.563. Additionally, it has been previously reported that phlorotannins of an edible brown seaweed \( Eisenia bicyclis \) exhibited a synergistic antibacterial effect with the FIC indices ranging from 0.502 to 1.000 against antibiotic-resistant \( P. acnes \) strains in combination with the antibiotics used in this study [5]. Kim et al. [38] reported a synergistic effect between an edible brown algae (\( Sargassum serratifolium \)) extract and the antibiotics, with the median \( \sum FIC \) indices from 0.270 to 0.550 against \( P. acnes \) strains. Compared with these results, it was clear that CCA in combination with the antibiotics showed comparably strong synergistic antibacterial effect against antibiotic-resistant acne-related bacteria.
Table 3. Minimum inhibitory concentration (MIC) and fractional inhibitory concentration (FIC) indices of chitosan–caffeic acid (CCA) in combination with antibiotics against antibiotic-resistant acne-related bacteria.

| Strains                  | Test Compound    | MIC (µg/mL) | Median $\Sigma$FIC $^1$ | $\Sigma$FIC$^2_{\text{max}}$ | $\Sigma$FIC$^3_{\text{min}}$ | Minimum Concentration for Observing Synergy |
|--------------------------|------------------|-------------|--------------------------|-------------------------------|-------------------------------|---------------------------------------------|
| *P. acnes* KCTC 3314     | CCA              | 256 32      | 0.533                    | 1.016                         | 0.188                         | 64.0 4.0                                   |
|                          | Tetracycline     |             |                          |                               |                               |                                             |
| *P. acnes* isolate 2874  | CCA              | 256 16      | 0.502                    | 1.004                         | 0.375                         | 64.0 4.0                                   |
|                          | Tetracycline     |             |                          |                               |                               |                                             |
| *P. acnes* KCTC 3314     | CCA              | 256 1024    | 0.502                    | 1.004                         | 0.188                         | 32.0 64.0                                  |
|                          | Erythromycin     |             |                          |                               |                               |                                             |
| *P. acnes* isolate 2874  | CCA              | 256 1024    | 0.502                    | 1.016                         | 0.313                         | 64.0 128.0                                 |
|                          | Erythromycin     |             |                          |                               |                               |                                             |
| *Pseudomonas aeruginosa* KCTC 1637 | CCA              | 16 16        | 0.5                      | 1.063                         | 0.266                         | 4.0 0.5                                   |
|                          | Erythromycin     |             |                          |                               |                               |                                             |
| *P. acnes* KCTC 3314     | CCA              | 256 1024    | 0.504                    | 1.016                         | 0.375                         | 64.0 256.0                                 |
|                          | Lincomycin       |             |                          |                               |                               |                                             |
| *P. acnes* isolate 2874  | CCA              | 256 1024    | 0.502                    | 1.016                         | 0.313                         | 64.0 256.0                                 |
|                          | Lincomycin       |             |                          |                               |                               |                                             |
| *P. aeruginosa* KCTC 1637 | CCA              | 16 64        | 0.375                    | 1.063                         | 0.266                         | 4.0 16.0                                   |
|                          | Lincomycin       |             |                          |                               |                               |                                             |

$^1 \Sigma$FIC, the sum of FICs; $^2 \Sigma$FIC$^2_{\text{max}}$, the highest; $^3 \Sigma$FIC$^3_{\text{min}}$, the lowest $\Sigma$FIC. The FIC index indicated synergistic effect: <0.5, marked synergy; 0.5 to <1.0, weak synergy; 1.0, additive; >1.0 to <2.0, subadditive; 2.0, indifferent; >2.0, antagonistic.
3. Discussion

In this research, we determined the antibacterial effect of chitosan-phytochemical conjugates on acne-related bacteria, such as *P. acnes*, *S. epidermidis*, *S. aureus*, and *P. aeruginosa*. The results of the antibacterial effect of chitosan-phytochemical conjugates against acne-related bacteria were in accordance with the previous reports that the chitosan-phytochemical conjugates exhibited higher antimicrobial effects than that of unconjugated chitosan [14,21]. The MICs of chitosan-phytochemical conjugates were in the range of 8 to 512 µg/mL against acne-related bacteria. Meanwhile, the MICs of the unmodified chitosan ranged from 128 to 1024 µg/mL. Thus, the chitosan-phytochemical conjugates possessed lower MIC values than those of the unconjugated chitosan, indicating that the conjugation increased antibacterial activity. As shown in Table 1, the antimicrobial efficacy of chitosan-phytochemical conjugates was proved to be strain dependent. Chitosan-phytochemical conjugates had higher antibacterial activity against *S. aureus*, *S. epidermis*, and *P. aeruginosa* than *P. acnes*. This may be due to the difference in the modes of antibacterial activity. Chitosan-phytochemical conjugates may increase the osmotic pressure-induced disruption and shrinkage of the bacterial membrane because of a reduction in the permeability of the membrane to intracellular components in *S. aureus*, *S. epidermis*, and *P. aeruginosa* [18,35]. In *P. acnes*, chitosan-phytochemical conjugates may operate via multiple mechanisms [39]. Like other studies proposed, the chitosan-phytochemical conjugates may also form a barrier on the bacterial surface and prevents the entry of nutrients [40]. Interestingly, chitosan and the chitosan-phytochemical conjugates showed very strong antibacterial activity against *P. aeruginosa* in the MIC range of 16 to 32 µg/mL, while Mazurova et al. [24] reported that MIC values of natural substances (gallic acid, methyl gallate, ethyl gallate, propyl gallate, octyl gallate, carvacrol, thymol, and eugenol) ranged from 300 to 2400 µg/mL. The mode of antibacterial activity is a complicated process that differs between Gram-positive and Gram-negative bacteria due to different cell surface characteristics. In several studies, stronger antibacterial activity was apparent against Gram-positive and Gram-negative bacteria [41]. Generally, *P. aeruginosa* has high-level resistance to antibiotics and substances derived from natural materials due to the low permeability and the action of multidrug efflux pumps [5,42]. Bacterial cell surface is a unique structure and a major target for the development of antibacterial agents. Positively charged chitosan and negatively charged bacterial cell surfaces interact with each other, leading to weakness of the cell wall accompanied by either cell lysis or cell wall damage alone [30,42]. In analogy to chitosan-polyphenol conjugates, the antibacterial activity of chitosan-phytochemical conjugates were accelerated by affecting the integrity of bacterial cell envelope and altering cell permeability resulting from interaction with the envelope [30,43]. To date, there have been several reports on the control of acne-related bacteria. However, these studies focused on the antibacterial activity of natural compounds derived from terrestrial organisms [31–33]. Furthermore, these compounds exhibited lower antibacterial activity against acne-related bacteria compared to the chitosan and chitosan-phytochemical conjugates [3,44]. Thus, to the best of our knowledge, this is the first study to show chitosan-phytochemical conjugates exhibiting antibacterial activity against acne-related bacteria.

In particular, both *P. acnes* strains have high-level resistant to erythromycin and lincomycin with MICs of 1024 µg/mL (Table 2). However, *P. acnes* isolate 2875 strain is an antibiotic susceptible bacterium to the three antibiotics. In addition, previously, we also reported the safety of chitosan conjugates in human keratinocyte cell lines [45]. Considering these points, chitosan and its phytochemical derivatives with broad spectrum antimicrobial activity are associated as being safe to animal cell lines and will be very useful for commercial exploitation in the pharmaceutical industry.

Among chitosan-conjugated derivatives, CCA showed the highest antibacterial activity and also exhibited the synergistic antibacterial effect in combination with tetracycline, erythromycin, and lincomycin against acne-related bacteria. Resistance to erythromycin, tetracycline, and lincomycin in *P. acnes* has primarily been related to target site mutations in the genes encoding the 23S rRNA, the 16S rRNA, and *erm(X)* [46]. The restored antibacterial activities with CCA and antibiotics against acne-related bacteria may help prevent mutations in the 23S rRNA gene, 16S rRNA, and *erm(X)*.
Although further experiments are needed to clarify the detailed mechanisms of the synergistic effect between CCA and commercial antibiotics to treat acne vulgaris, synergistic antibacterial effects of CCA suggest that CCA may restore the antibacterial activity of old commercial antibiotics, which had lost their antibacterial activity against some antibiotic-resistant bacteria. In this study, the chitosan-phytochemical conjugate might potentially be used as the alternative treatment of the antibiotic-resistant bacteria. However, some issues still remain to be examined in future studies. For example, an important issue is to explain the restoring mechanism of antibacterial activity of old antibiotics that have lost their effectiveness in treatment. It was previously reported that β-lactam antibiotics will restore the antibacterial activity against MRSA through the suppression of penicillin-binding protein 2a production, a key determinant for β-lactam antibiotic resistance, by chitosan-phytochemical conjugates [14]. Likewise, further study will determine the restored antibacterial activities with the detection of the 23S rRNA, the 16S rRNA, and erm(X) of P. acnes treated with CCA. This study highlights the limitations of current antimicrobial treatment strategies in patients with serious P. acnes infections.

4. Materials and Methods

4.1. Preparation of Chitosan-Phytochemical Conjugates

Chitosan produced from crab shell (Chionoecetes japonicus) chitin with a degree of deacetylation of 90% and average MW 310 kDa was provided from Kitto Life Co. (Seoul, Korea). Phytochemicals including caffeic acid, ferulic acid, and sinapic acid were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). All other chemicals and reagents used in this study were of analytical grade and commercially available. Chitosan-phytochemical conjugates were kindly provided by Prof. Jae-Young Je, Pukyong National University (Busan, Korea). The conjugates were prepared according to the previously reported method [13]. In brief, chitosan (0.25 g) was dissolved in 2% acetic acid (25 mL), and then 1.0 M hydrogen peroxide (0.5 mL) containing ascorbic acid (0.054 g) was added. Exactly 0.14 mM of phytochemicals (caffeic acid, ferulic acid, and sinapic acid) were added to the mixture after incubating at room temperature for 30 min, and then reacted for 24 h at room temperature. Results of the chitosan-phytochemical conjugates consisted of chitosan-caffeic acid conjugate (CCA), chitosan-ferulic acid conjugate (CFA), and chitosan-sinapic acid conjugate (CSA), respectively. A control (unmodified chitosan) was also treated with the same procedures without the addition of phytochemicals.

4.2. Bacterial Strains and Culture Conditions

The type bacterial strains were purchased from the Korean Collection for Type Cultures (KCTC; Daejeon, Korea); P. acnes KCTC 3314, S. aureus KCTC 1927, S. epidermidis KCTC 1370, and P. aeruginosa KCTC 1637. Two P. acnes clinical isolates were obtained from the Gyeongsang National University Hospital (Jinju, Korea), a member of the National Biobank of Korea. P. acnes strains were anaerobically cultured in brain heart infusion broth (Difco, Detroit, MI, USA) with 1.0% glucose supplement, and incubated in a CO2 incubator at 10% CO2-humidified atmosphere and 37 °C for 72 h (NAPCO 5400; General Laboratory Supply, Pasadena, TX, USA) in a 10% CO2-humidified atmosphere. Other bacteria were aerobically cultivated in Mueller–Hinton broth (MHB; Difco) at 37 °C. The broth dilution method was carried out in MHB according to the Clinical and Laboratory Standards Institute guidelines [47].

4.3. Determination of Minimum Inhibitory Concentration (MIC) and Fractional Inhibitory Concentration (FIC) Index

MIC was defined as the lowest concentration of crude extract that inhibited the visual growth after incubating the aerobic bacteria for 18 h and the anaerobic bacteria for 48 h. MIC values of the chitosan-phytochemical conjugate were determined by the two-fold serial dilution method in 96-well flat-bottomed microtitration plates at a final concentration of $7 \times 10^5$ CFU/mL. The microtitration
plates were read visually and the MIC of the chitosan-phytochemical conjugate that exhibited no turbidity was recorded as the MIC [5]. The interaction between chitosan-phytochemical conjugates and antibiotics including tetracycline, erythromycin, and lincomycin against acne-related bacteria was evaluated following the checkerboard method [48]. The synergy effect between chitosan-phytochemical conjugates and the antibiotics was tested as an FIC index [48]. Each FIC index was determined using the following equation:

$$\sum \text{FIC} = \text{FIC}_A + \text{FIC}_B = \frac{C_A}{\text{MIC}_A} + \frac{C_B}{\text{MIC}_B}$$

where MIC$_A$ and MIC$_B$ are the MICs of drugs A and B alone, respectively, and C$_A$ and C$_B$ are the concentrations of the drugs in combination, respectively. The synergistic effect was evaluated as an FIC index. The interaction was defined as synergistic if the FIC index was <1.0, additive if the FIC index was 1.0, subadditive if the FIC index was between 1.0 to <2.0, indifferent if the FIC index was 2, and antagonistic if the FIC index >2. Synergy was further sub-classified as marked (FIC index, <0.50) and weak (FIC index, between 0.50 to <1.0).

5. Conclusions

In this study, we evaluated the antibacterial activity of chitosan-phytochemical conjugates against acne-related bacteria, such as P. acnes, S. epidermidis, S. aureus, and P. aeruginosa. Among the chitosan-phytochemical conjugates tested, CCA possessed significant antibacterial properties against acne-related bacteria. Furthermore, the combination of CCA with antibiotics used in the treatment of acne vulgaris resulted in a restoration of the effectiveness of commercial antibiotics used to treat skin pathogenic bacteria. Thus, the present study strongly suggested that chitosan-phytochemical conjugates such as CCA will be a good candidate for developing an alternative therapeutic agent with fewer side effects for the treatment of acne vulgaris.

Acknowledgments: This research was funded by the Marine Biotechnology Program (20150220) funded by the ministry of Oceans and Fisheries, Republic of Korea. This work was also supported by the special fund of Pukyong National University, donated by the SKS Trading Co. in Lynnwood, WA, USA, in memory of the late Young Hwan Kang for his inspiration and deep concern of fisheries science. The pathogen for this study was obtained by the Gyeongsang National University Hospital Branch of National Culture Collection for Pathogens (GNUH-NCCP).

Author Contributions: Ji-Hoon Kim and Young-Mog Kim conceived of and designed the experiments. Daeung Yu, Sung-Hwan Eom and Song-Hee Kim contributed reagents/materials/analysis tools and performed experiments. Junghwan Oh and Won-Kyo Jung analyzed the data. Daeung Yu, Sung-Hwan Eom, and Young-Mog Kim wrote the paper.

Conflicts of Interest: The authors declare no conflicts of interest.

References
1. Charakida, A.; Seaton, E.D.; Charakida, M.; Mouser, P.; Avgerinos, A.; Chu, A.C. Phototherapy in the treatment of acne vulgaris. Am. J. Clin. Dermatol. 2004, 5, 211–216. [CrossRef] [PubMed]
2. Dai, T.; Huang, Y.Y.; Hamblin, M.R. Photodynamic therapy for localized infections—State of the art. Photodisin. Photodyn. Ther. 2009, 6, 170–188. [CrossRef] [PubMed]
3. Yamaguchi, N.; Satoh, K.; Ono, M. In vitro evaluation of antibacterial, anticollagenase, and antioxidant activities of hop components (Humulus lupulus) addressing acne vulgaris. Phytomedicine 2009, 16, 369–376. [CrossRef] [PubMed]
4. Choi, J.S.; Bae, H.J.; Kim, S.J.; Choi, I.S. In vitro antibacterial and anti-inflammatory properties of seaweed extracts against acne inducing bacteria, Propionibacterium acnes. J. Environ. Biol. 2011, 32, 313–318. [PubMed]
5. Lee, J.H.; Eom, S.H.; Lee, E.H.; Jung, Y.J.; Kim, H.J.; Jo, M.R.; Son, K.T.; Lee, H.J.; Kim, J.H.; Lee, M.S.; et al. In vitro antibacterial and synergistic effect of phlorotannins isolated from edible brown seaweed Eisenia bicyclis against acne-related bacteria. Algae 2014, 29, 47–55. [CrossRef]
6. Gollnick, H.; Cunliffe, W.; Berson, D.; Dreno, B.; Finlay, A.; Leyden, J.J.; Shalita, A.R.; Thiboutot, D. Management of acne: A report from a global alliance to improve outcomes in acne. J. Am. Acad. Dermatol. 2003, 49, 1–37. [CrossRef] [PubMed]

7. Han, S.M.; Lee, K.G.; Yeo, J.H.; Baek, H.J.; Park, K. Antibacterial and anti-inflammatory effects of honeybee (Apis mellifica) venom against acne-inducing bacteria. J. Med. Plants Res. 2010, 4, 459–464.

8. Kim, J.Y.; Oh, T.H.; Kim, B.J.; Kim, S.S.; Lee, N.H.; Hyun, C.G. Chemical composition and anti-inflammatory effects of essential oil from Farfugium japonicum flower. J. Oleo Sci. 2008, 57, 623–628. [CrossRef] [PubMed]

9. Singh, D.; Hatwar, B.; Nayak, S. Herbal plants and Propionibacterium acnes: An overview. Int. J. Biomed. Res. 2011, 2, 486–498. [CrossRef]

10. Zu, Y.; Yu, H.; Liang, L.; Fu, Y.; Efferth, T.; Liu, X.; Wu, N. Activities of ten essential oils towards Propionibacterium acnes and PC-3, A-549 and MCF-7 cancer cells. Molecules 2010, 15, 3200–3210. [CrossRef] [PubMed]

11. Younes, I.; Rinaudo, M. Chitin and chitosan preparation from marine sources. Structure, properties and applications. Mar. Drugs 2015, 13, 1133–1174. [CrossRef] [PubMed]

12. Szymanska, E.; Winnicka, K. Stability of chitosan—a challenge for pharmaceutical and biomedical applications. Mar. Drugs 2015, 13, 1819–1846. [CrossRef] [PubMed]

13. Cho, Y.S.; Kim, S.K.; Ahn, C.B.; Je, J.Y. Preparation, characterization, and antioxidant properties of gallic acid-grafted-chitosans. Carbohydr. Polym. 2011, 83, 1617–1622. [CrossRef]

14. Eom, S.H.; Kang, S.K.; Lee, D.S.; Myeong, J.I.; Lee, J.H.; Kim, H.W.; Kim, K.H.; Je, J.Y.; Jung, W.K.; Kim, Y.M. Synergistic antibacterial effect and antibacterial action mode of chitosan-ferulic acid conjugate against methicillin-resistant Staphylococcus aureus. J. Microbiol. Biotechnol. 2016, 26, 784–789. [CrossRef] [PubMed]

15. Lee, S.H.; Ryu, B.; Je, J.Y.; Kim, S.K. Diethylaminoethyl chitosan induces apoptosis in HeLa cells via activation caspase-3 and p53 expression. Carbohydr. Polym. 2011, 84, 571–578. [CrossRef]

16. Satheeshbabu, B.K.; Shivakumar, K.L. Synthesis of conjugated chitosan and its effect on drug permeation from transdermal patches. Indian J. Pharm. Sci. 2013, 75, 162. [PubMed]

17. Alves, N.M.; Mano, J.F. Chitosan derivatives obtained by chemical modifications for biomedical and environmental applications. Int. J. Biol. Macromol. 2008, 43, 401–414. [CrossRef] [PubMed]

18. Je, J.Y. Preparation of chitosan-catechin conjugates and their antioxidant activity. J. Chit. Chit. 2012, 17, 123–128.

19. Xie, W.; Xu, P.; Liu, Q. Antioxidant activity of water-soluble chitosan derivatives. Bioorg. Med. Chem. Lett. 2011, 21, 1699–1701. [CrossRef]

20. Yoon, H.J.; Moon, M.E.; Park, H.S.; Im, S.Y.; Kim, Y.H. Chitosan oligosaccharide (COS) inhibits LPS-induced inflammatory effects in RAW 264.7 macrophage cells. Biochem. Biophys. Res. Commun. 2007, 358, 954–959. [CrossRef] [PubMed]

21. Lee, D.S.; Woo, J.Y.; Ahn, C.B.; Je, J.Y. Chitosan-hydroxyxycinnamic acid conjugates: Preparation, antioxidant and antimicrobial activity. Food Chem. 2014, 148, 97–104. [CrossRef] [PubMed]

22. Doshi, P.; Adsule, P.; Banerjee, K.; Outkar, D. Phenolic compounds, antioxidant activity and insulinotropic effect of extracts prepared from grape (Vitis vinifera L.) byproducts. J. Food Sci. Technol. 2015, 52, 181–190. [CrossRef] [PubMed]

23. Moo-Huchin, V.M.; Moo-Huchin, M.I.; Estrada-León, R.J.; Cuevas-Glory, L.; Estrada-Mota, I.A.; Ortiz-Vázquez, E.; Betancur-Anconad, D.; Sauri-Duch, E. Antioxidant compounds, antioxidant activity and phenolic content in peel from three tropical fruits from Yucatan, Mexico. Food Chem. 2015, 166, 17–22. [CrossRef] [PubMed]

24. Mazurova, J.; Kukla, R.; Rozkot, M.; Lustykova, A.; Slehova, E.; Sleha, R.; Lipensky, J.; Opletal, L. Use of natural substances for boar semen decontamination. Vet. Med. 2015, 60, 235–247. [CrossRef]

25. Lee, S.M.; Liu, K.H.; Liu, Y.Y.; Chang, Y.P.; Lin, C.C.; Chen, Y.S. Chitosonic® acid as a novel cosmetic ingredient: Evaluation of its antimicrobial, antioxidant and hydration activities. Materials 2013, 6, 1391–1402. [CrossRef]

26. Tsai, T.H.; Tsai, T.H.; Wu, W.H.; Tseng, J.T.P.; Tsai, P.J. In vitro antimicrobial and anti-inflammatory effects of herbs against Propionibacterium acnes. Food Chem. 2010, 119, 964–968. [CrossRef]

27. Lee, D.S.; Cho, Y.S.; Je, J.Y. Antioxidant and antibacterial activities of chitosan-phloroglucinol conjugate. Fish. Aquat. Sci. 2013, 16, 229–235. [CrossRef]
28. Kim, D.H.; Je, J.Y. Antimicrobial activity of gallic acid-grafted-chitosan against fish pathogens. *J. Carbohydr. Chem.* **2015**, *34*, 163–171. [CrossRef] [PubMed]

29. Meynadier, J.; Alirezaei, M. Systemic antibiotics for acne. *Dermatology* **1998**, *196*, 135–139. [CrossRef] [PubMed]

30. Lee, D.S.; Eom, S.H.; Kim, Y.M.; Kim, H.S.; Yim, M.J.; Lee, S.H.; Kim, D.H.; Je, J.Y. Antibacterial and synergic effects of gallic acid-grafted-chitosan with β-lactams against methicillin-resistant *Staphylococcus aureus* (MRSA). *Can. J. Microbiol.* **2014**, *60*, 629–638. [CrossRef] [PubMed]

31. Oprica, C.; Emtestam, L.; Lapins, J.; Borglund, E.; Nyberg, F.; Stenlund, K.; Lundeberg, L.; Sillerström, E.; Nord, C.E. Antibiobiotic-resistant *Propionibacterium acnes* on the skin of patients with moderate to severe acne in Stockholm. *Anaerobe* **2004**, *10*, 155–164. [CrossRef] [PubMed]

32. Soussy, C.J.; Cluzel, R.; Courvalin, P. Definition and Determination of in vitro antibiotic susceptibility breakpoints for bacteria in France. *Eur. J. Clin. Microbiol. Infect. Dis.* **1994**, *13*, 238–246. [CrossRef] [PubMed]

33. Eom, S.H.; Park, J.H.; Yu, D.U.; Choi, J.I.; Choi, J.D.; Lee, M.S.; Kim, Y.M. Antimicrobial activity of brown alga *Eisenia bicyclis* against methicillin-resistant *Staphylococcus aureus*. *Fish. Aquat. Sci.* **2011**, *14*, 251–256. [CrossRef] [PubMed]

34. Kim, K.H.; Eom, S.H.; Kim, H.J.; Lee, D.S.; Nshimiyumukiza, O.; Kim, S.D.; Kim, Y.M.; Lee, M.S. Antifungal and synergic effects of an ethyl acetate extract of the edible brown seaweed *Eisenia bicyclis* against *Candida* species. *Fish. Aquat. Sci.* **2015**, *18*, 241–247.

35. Kim, K.H.; Eom, S.H.; Kim, J.H.; Jung, W.K.; Kim, D.H.; Kim, Y.M. In vitro antibacterial and synergic activity of an *Ecklonia cava* extract against antibiotic-resistant *Streptococcus parauberis*. *Fish. Aquat. Sci.* **2015**, *18*, 241–247.

36. Kim, Y.H.; Kim, J.H.; Kim, D.H.; Kim, H.R.; Kim, Y.M. Synergistic antifungal effect of *Sargassum serratifolium* (C. Agardh) C. Agardh extract against *Propionibacterium acnes* isolated from Chinese patients with acne vulgaris. *J. Carbohydr. Chem.* **2016**, *108*, 1128–1134. [CrossRef] [PubMed]

37. Nshimiyumukiza, O.; Kang, S.K.; Kim, H.J.; Lee, E.H.; Han, H.N.; Kim, Y.H.; Kim, D.H.; Kim, J.H.; Eom, S.H.; Kim, Y.M. Synergic antibacterial activity of *Ecklonia cava* (Phaeophyceae: Laminariales) against *Listeria monocytogenes* (Bacillales: Listeriaceae). *Fish. Aquat. Sci.* **2015**, *18*, 1–6. [CrossRef] [PubMed]

38. Soussy, C.J.; Cluzel, R.; Courvalin, P. Definition and Determination of in vitro antibiotic susceptibility breakpoints for bacteria in France. *Eur. J. Clin. Microbiol. Infect. Dis.* **1994**, *13*, 238–246. [CrossRef] [PubMed]

39. Champer, J.; Patel, J.; Fernando, N.; Salehi, E.; Wong, V.; Kim, J. Chitosan against cutaneous pathogens. *AMB Express* **2013**, *3*, 37. [CrossRef] [PubMed]

40. Kong, M.; Chen, X.G.; Xing, K.; Park, H.J. Antimicrobial properties of chitosan and mode of action: A state of the art review. *Int. J. Food Microbiol.* **2010**, *144*, 51–63. [CrossRef] [PubMed]

41. Bonomo, R.A.; Szabo, D. Mechanisms of multidrug resistance in *Acinetobacter* species and *Pseudomonas aeruginosa*. *Clin. Infect. Dis.* **2006**, *43*, S49–S56. [CrossRef] [PubMed]

42. Eaton, P.; Fernandes, J.C.; Pereira, E.; Pintado, M.E.; Malcata, F.X. Atomic force microscopy study of the antibacterial effects of chitosans on *Escherichia coli* and *Staphylococcus aureus*. *Ultramicroscopy* **2008**, *108*, 1128–1134. [CrossRef] [PubMed]

43. Chen, C.Z.S.; Cooper, S.L. Interactions between dendrimer biocides and bacterial membranes. *Biomaterials* **2002**, *23*, 3359–3368. [CrossRef]

44. Sánchez-Maldonado, A.F.; Schieber, A.; Gänzle, M.G. Structure-function relationships of the antibacterial activity of phenolic acids and their metabolism by lactic acid bacteria. *J. Appl. Microbiol.* **2011**, *111*, 1176–1184. [CrossRef] [PubMed]

45. Kim, J.H.; Je, J.Y.; Kim, Y.M. Anti-inflammatory effects of chitosan–phytochemical conjugates against *Propionibacterium acnes*-induced inflammation. *Korean J. Fish. Aquat. Sci.* **2016**, *49*, 589–593.

46. Fan, Y.; Hao, F.; Wang, W.; Lu, Y.; He, L.; Wang, G.; Chen, W. Multicenter cross-sectional observational study of antibiotic resistance and the genotypes of *Propionibacterium acnes* isolated from Chinese patients with acne vulgaris. *J. Dermatol.* **2015**, *43*, 406–413. [CrossRef] [PubMed]
47. Clinical and Laboratory Standards Institute (CLSI). *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically Approved Standard*, 9th ed.; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2006.

48. Norden, C.W.; Wentzel, H.; Keleti, E. Comparison of techniques for measurement of in vitro antibiotic synergism. *J. Infect. Dis.* **1979**, *140*, 629–633. [CrossRef] [PubMed]

© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).